# Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

> **NCT05641142** · NA · RECRUITING · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 100 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Rendu Osler Disease

## Interventions

- **OTHER:** monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease

## Key facts

- **NCT ID:** NCT05641142
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-07
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641142, "Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05641142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*